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Background: BiDil, a 2005 US Food and Drug Administration approved drug for congestive heart failure, has a unique indication limiting its use 
to only African-Americans. Given BiDil’s controversial labeling, this study aims to: 1) Evaluate the context in which cardiologists use the race-based 
pharmaceutical and generic versions of isosorbide dinitrate/hydralazine, 2) Elucidate factors shaping BiDil recommendation, and 3) Determine BiDil 
prescription variations with a range of demographic factors.
Methods: A web-based survey was sent to a sample of the Association of Black Cardiologists’ board certified members of as of July 2009. Thirty-six 
physicians provided input on 28 research ethics questions aimed at deciding whether race should be used as a method of personalizing medical 
treatments.
Results: 63.9% of respondents have prescribed patients the branded form of BiDil. Numerous respondents (66.7%) indicated use of subjective 
means to determine their patients’ race through observing physical features (skin color, hair-type, etc.) and 60%, additionally have patients complete 
a census category based form to gather race data. In determining which patients should receive BiDil, most physicians use medical history (68.4%), 
fewer use race based on physician assessment (42.1%), and even fewer use race based on patient identification (36.8%). The foremost factor 
deterring cardiologists from prescribing BiDil was preference for generic versions of hydralazine and isosorbide dinitrate (63.6%). Another finding 
showed 58.6% of physicians surveyed believe racially defined groups are biologically distinct.
Conclusions: This is the first empirical study assessing clinician perception of the prototype for race-based pharmaceuticals, BiDil. Given the 
ongoing focus of researchers to personalize medicine and the potential for personalizing to mean focusing on racial groups, there is a growing need 
to understand whether drug labels focusing on particular racial groups provide feasible ways of tailoring medication or actually lead to unintended 
problems. Hence, the results of this study will elucidate perceptions of cardiologists with regard to the unique race-focused drug labeling of BiDil.
